Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab: Editorial comment

Samir S. Taneja

    Research output: Contribution to journalComment/debatepeer-review

    Fingerprint

    Dive into the research topics of 'Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab: Editorial comment'. Together they form a unique fingerprint.